Literature DB >> 33502479

Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease-Another Hopeful Step Forward.

Joseph Clemente Alvarnas1.   

Abstract

Entities:  

Year:  2021        PMID: 33502479     DOI: 10.1001/jamanetworkopen.2020.35719

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


× No keyword cloud information.
  1 in total

1.  Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.

Authors:  Shuang Fan; Wen-Xuan Huo; Yang Yang; Meng-Zhu Shen; Xiao-Dong Mo
Journal:  Front Immunol       Date:  2022-08-04       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.